These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 18204196

  • 1. Antibody response to inactivated subunit influenza vaccine in patients with Wegener's granulomatosis.
    Zycinska K, Romanowska M, Nowak I, Rybicka K, Wardyn KA, Brydak LB.
    J Physiol Pharmacol; 2007 Nov; 58 Suppl 5(Pt 2):819-28. PubMed ID: 18204196
    [Abstract] [Full Text] [Related]

  • 2. Humoral response to hemagglutinin components of influenza vaccine in patients with non-Hodgkin malignant lymphoma.
    Brydak LB, Machała M, Centkowski P, Warzocha K, Biliński P.
    Vaccine; 2006 Nov 10; 24(44-46):6620-3. PubMed ID: 16870313
    [Abstract] [Full Text] [Related]

  • 3. Antibody response to influenza vaccination in patients suffering from asthma.
    Romanowska M, Rybicka K, Nowak I, Józefczuk J, Zycinska K, Radzikowski A, Brydak LB.
    J Physiol Pharmacol; 2007 Nov 10; 58 Suppl 5(Pt 2):583-9. PubMed ID: 18204172
    [Abstract] [Full Text] [Related]

  • 4. Cell-mediated immune responses to influenza vaccination in Wegener's granulomatosis.
    Holvast A, de Haan A, van Assen S, Stegeman CA, Huitema MG, Huckriede A, Benne CA, Westra J, Palache A, Wilschut J, Kallenberg CG, Bijl M.
    Ann Rheum Dis; 2010 May 10; 69(5):924-7. PubMed ID: 19596692
    [Abstract] [Full Text] [Related]

  • 5. Wegener's granulomatosis patients show an adequate antibody response to influenza vaccination.
    Holvast A, Stegeman CA, Benne CA, Huckriede A, Wilschut JC, Palache AM, Kallenberg CG, Bijl M.
    Ann Rheum Dis; 2009 Jun 10; 68(6):873-8. PubMed ID: 18625625
    [Abstract] [Full Text] [Related]

  • 6. Antibody response to influenza vaccine in coronary artery disease: a substudy of the FLUCAD study.
    Brydak LB, Romanowska M, Nowak I, Ciszewski A, Bilińska ZT.
    Med Sci Monit; 2009 Jul 10; 15(7):PH85-91. PubMed ID: 19564837
    [Abstract] [Full Text] [Related]

  • 7. Randomized, double-blind comparative trial of subunit and virosomal influenza vaccines for immunocompromised patients.
    Evison J, Farese S, Seitz M, Uehlinger DE, Furrer H, Mühlemann K.
    Clin Infect Dis; 2009 May 15; 48(10):1402-12. PubMed ID: 19361304
    [Abstract] [Full Text] [Related]

  • 8. Safety and immunogenicity of two subunit influenza vaccines in healthy children, adults and the elderly: a randomized controlled trial in China.
    Zhu FC, Zhou W, Pan H, Lu L, Gerez L, Nauta J, Giezeman K, de Bruijn I.
    Vaccine; 2008 Aug 18; 26(35):4579-84. PubMed ID: 18602729
    [Abstract] [Full Text] [Related]

  • 9. Long-lasting immunogenicity of a virosomal vaccine in older children and young adults with type I diabetes mellitus.
    Zuccotti GV, Scaramuzza A, Riboni S, Mameli C, Pariani E, Tanzi E, Zanetti A, Radaelli G.
    Vaccine; 2009 Aug 27; 27(39):5357-62. PubMed ID: 19607951
    [Abstract] [Full Text] [Related]

  • 10. Characteristic of humoral response of elderly to inactivated influenza vaccine.
    Siennicka J.
    Arch Immunol Ther Exp (Warsz); 1996 Aug 27; 44(5-6):389-94. PubMed ID: 9017157
    [Abstract] [Full Text] [Related]

  • 11. Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model.
    Hagenaars N, Mastrobattista E, Glansbeek H, Heldens J, van den Bosch H, Schijns V, Betbeder D, Vromans H, Jiskoot W.
    Vaccine; 2008 Dec 02; 26(51):6555-63. PubMed ID: 18848856
    [Abstract] [Full Text] [Related]

  • 12. Trivalent inactivated subunit influenza vaccine Influvac: 25-Year experience of safety and immunogenicity.
    Giezeman KM, Nauta J, de Bruijn IA, Palache AM.
    Vaccine; 2009 Apr 21; 27(18):2414-7. PubMed ID: 19368782
    [Abstract] [Full Text] [Related]

  • 13. Effect of a second, booster, influenza vaccination on antibody responses in quiescent systemic lupus erythematosus: an open, prospective, controlled study.
    Holvast A, van Assen S, de Haan A, Huckriede A, Benne CA, Westra J, Palache A, Wilschut J, Kallenberg CG, Bijl M.
    Rheumatology (Oxford); 2009 Oct 21; 48(10):1294-9. PubMed ID: 19692457
    [Abstract] [Full Text] [Related]

  • 14. Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant.
    Goji NA, Nolan C, Hill H, Wolff M, Noah DL, Williams TB, Rowe T, Treanor JJ.
    J Infect Dis; 2008 Sep 01; 198(5):635-41. PubMed ID: 18694338
    [Abstract] [Full Text] [Related]

  • 15. Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide.
    Knight A, Askling J, Granath F, Sparen P, Ekbom A.
    Ann Rheum Dis; 2004 Oct 01; 63(10):1307-11. PubMed ID: 15130900
    [Abstract] [Full Text] [Related]

  • 16. Compassionate treatment of Wegener's granulomatosis with rabbit anti-thymocyte globulin.
    Hagen EC, de Keizer RJ, Andrassy K, van Boven WP, Bruijn JA, van Es LA, van der Woude FJ.
    Clin Nephrol; 1995 Jun 01; 43(6):351-9. PubMed ID: 7554518
    [Abstract] [Full Text] [Related]

  • 17. Subunit influenza vaccines produced from cell culture or in embryonated chicken eggs: comparison of safety, reactogenicity, and immunogenicity.
    Reisinger KS, Block SL, Izu A, Groth N, Holmes SJ.
    J Infect Dis; 2009 Sep 15; 200(6):849-57. PubMed ID: 19673652
    [Abstract] [Full Text] [Related]

  • 18. Immunogenicity and safety of low dose virosomal adjuvanted influenza vaccine administered intradermally compared to intramuscular full dose administration.
    Künzi V, Klap JM, Seiberling MK, Herzog C, Hartmann K, Kürsteiner O, Kompier R, Grimaldi R, Goudsmit J.
    Vaccine; 2009 Jun 02; 27(27):3561-7. PubMed ID: 19464535
    [Abstract] [Full Text] [Related]

  • 19. The virosomal influenza vaccine Invivac: immunogenicity and tolerability compared to an adjuvanted influenza vaccine (Fluad in elderly subjects.
    de Bruijn IA, Nauta J, Gerez L, Palache AM.
    Vaccine; 2006 Nov 10; 24(44-46):6629-31. PubMed ID: 16901593
    [Abstract] [Full Text] [Related]

  • 20. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial.
    Wu J, Fang HH, Chen JT, Zhou JC, Feng ZJ, Li CG, Qiu YZ, Liu Y, Lu M, Liu LY, Dong SS, Gao Q, Zhang XM, Wang N, Yin WD, Dong XP.
    Clin Infect Dis; 2009 Apr 15; 48(8):1087-95. PubMed ID: 19281330
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.